Changes in Beneficial Ownership · 4
Mirum Pharmaceuticals, Inc.
MIRMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10072026_121019.xml
Filing details
- Report period
- 2026-10-06
- Issuer
- Mirum Pharmaceuticals, Inc.
- Issuer CIK
- 0001759425
- Trading symbol
- MIRM
Reporting owner 1
- Name
- Peetz Christopher
- Reporting owner CIK
- 0001614740
- Relationship
- Director · Officer
- Officer title
- CHIEF EXECUTIVE OFFICER
- Address
- C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY, CA, 94404
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-06 | M · Form 4 | 5,305 | A | 19.19 | 199,745 | D |
| Common Stock | 2026-10-06 | M · Form 4 | 6,892 | A | 15.87 | 206,637 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 187,500 | I | By The Peetz Family Trust |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | 19.19 | 2026-10-06 | M · Form 4 | 5,305 | D | 0 | [F1] | 2031-01-06 | Common Stock | 5,305 | 169,695 | D |
| Employee Stock Option (right to buy) | 15.87 | 2026-10-06 | M · Form 4 | 6,892 | D | 0 | [F1] | 2032-01-05 | Common Stock | 6,892 | 233,108 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Judit Ryvkin, Attorney-in-Fact
- Date
- 2026-10-06
Company context
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).